ArticleBMC nephrology2026
Acetate ameliorates membranous nephropathy by modulating the immune response and podocyte function.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMembranous nephropathy (MN) is an antibody-mediated podocytopathy in which subepithelial immune deposits and complement activation lead to podocyte injury and proteinuria. Short-chain fatty acids (SCFAs) are microbiota-derived metabolites with immunomodulatory properties, but their therapeutic potential and mechanisms in MN remain incompletely defined. MATERIALS AND
methodsWe evaluated acetate, propionate, and butyrate in a passive Heymann nephritis (PHN) rat model (n = 6/group). Rats received 150 mM sodium acetate, propionate, or butyrate in drinking water from day 0 to day 42. Proteinuria and biochemical indices were monitored; glomerular immune deposition and ultrastructure were assessed by immunofluorescence and transmission electron microscopy. Antigen-specific antibodies were quantified by ELISA. Glomerular expression of synaptopodin and WT1 was detected by immunohistochemistry. Splenic CD4
resultsAll three SCFAs significantly reduced proteinuria in PHN rats compared with disease controls and ameliorated ultrastructural injury, including GBM thickening and podocyte foot-process effacement. Acetate and propionate reduced subepithelial immune-complex deposits. Acetate selectively decreased antigen-specific anti-sheep IgG responses without altering total IgG. PHN was associated with decreased Tregs and increased Th1/Th17 polarization; acetate increased the Treg proportion in splenocytes. Acetate protected podocyte cytoskeletal integrity and viability in vivo. Acetate acted through GPR43, as the GPR43 antagonist GLPG0974 partially or completely blocked acetate's effects on ROS reduction, migration improvement, and synaptopodin mRNA upregulation. Acetate treatment reduced HDAC activity in both renal cortex and podocytes while increasing HAT activity. Acetate mitigated primary MN plasma-induced dysfunction by improving migration and synaptopodin signal, reducing ROS, limiting apoptosis, and restoring cell viability.
conclusionAcetate ameliorates experimental MN through coordinated immunomodulatory effects and amelioration of podocyte foot process effacement. These findings support targeting acetate pathways as a mechanistically plausible adjunct strategy with low potential toxicity for MN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.